Checkmate Pharmaceuticals, Inc. (CMPI) SEC Filing 10-Q Quarterly Report for the period ending Thursday, March 31, 2022

Checkmate Pharmaceuticals, Inc.

CIK: 1651431 Ticker: CMPI


Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results

and Provides Business Update

Alan Bash, experienced biopharmaceutical executive, appointed President and CEO

Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer indications

ongoing; Trial dosing initiated in cohorts for PD-1 refractory non-melanoma skin cancers.

Preliminary clinical data readouts anticipated in second half of 2022

CAMBRIDGE, Mass., March 29, 2022Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced full year 2021 financial results and provided a business update.

“Our vidutolimod program continued to advance in 2021 and expand into multiple cancer indications,” said Alan Bash, President and Chief Executive Officer of Checkmate. “Driving vidutolimod forward to multiple clinical data readouts and towards registration in refractory melanoma remains our top strategic priority. I look forward to advancing our leadership in innate immunity and driving the success of Checkmate with our highly talented executive team and Board of Directors.”

Recent Business Updates



Alan Bash, accomplished global biopharmaceutical executive with over 20 years of strategic and operational leadership at Bristol Myers Squibb, was appointed President and CEO. Mr. Bash also joined the Board of Directors.



Jon Wigginton, M.D. and Joy Yan, M.D., Ph.D., both industry leaders in immuno-oncology clinical development, joined the Board of Directors.



Patient dosing was initiated in a Phase 2 multi-indication study evaluating the efficacy and safety of vidutolimod in combination with cemiplimab supported by a clinical collaboration with Regeneron; cohorts focused on anti-PD-1 refractory cutaneous squamous cell carcinoma and Merkel cell carcinoma are currently enrolling.



Patient recruitment activities and enrollment continue across our other ongoing clinical trials evaluating vidutolimod, including:



A Phase 2 trial of vidutolimod in combination with nivolumab in anti-PD-1 refractory advanced melanoma, supported by a clinical collaboration with Bristol Myers Squibb.



A randomized Phase 2/3 trial of vidutolimod in combination with nivolumab vs. nivolumab monotherapy in first-line metastatic or unresectable melanoma, also supported by the clinical collaboration with Bristol Myers Squibb.



A Phase 2 trial of vidutolimod in combination with pembrolizumab in recurrent or metastatic squamous cell head and neck cancer.

The following information was filed by Checkmate Pharmaceuticals, Inc. (CMPI) on Wednesday, March 30, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Checkmate Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Checkmate Pharmaceuticals, Inc..


Assess how Checkmate Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Checkmate Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors




Learn More
Bullish Bearish Neutral
Filter by Sentiment:
Filter by Category:
M & A
Filter by Subcategory:
Cash Flow
Inside Checkmate Pharmaceuticals, Inc.'s 10-Q Quarterly Report:

Material Contracts, Statements, Certifications & more

Checkmate Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: CMPI
CIK: 1651431
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-22-148774
Submitted to the SEC: Thu May 12 2022 4:49:16 PM EST
Accepted by the SEC: Thu May 12 2022
Period: Thursday, March 31, 2022
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: